Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs

Brain Research Reviews

Volumn 31, Issue 2-3, 2000, Pages 320-329

  Svensson, Torgny H ^a  

^a Sect Neuropsychopharmacology   (Sweden)

Author keywords

Atypical antipsychotic drugs; Dopamine; Phencyclidine; Schizophrenia

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMPA RECEPTOR ANTAGONIST; CLOZAPINE; DIZOCILPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; PSYCHEDELIC AGENT; RACLOPRIDE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ANIMAL MODEL; AVOIDANCE BEHAVIOR; BEHAVIOR; BRAIN DYSFUNCTION; BRAIN REGION; CONDITIONING; CONFERENCE PAPER; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG MECHANISM; ELECTROPHYSIOLOGY; HUMAN; LIMBIC CORTEX; LOCOMOTION; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; NERVE ENDING; NERVE PROJECTION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE UNIT ACTIVITY; VENTRAL TEGMENTUM;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; HALLUCINOGENS; HUMANS; NEURONS; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 0034009789     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(99)00048-X     Document Type: Conference Paper

References (105)

1. Abi-Dargham A., Laurelle M., Aghajanian G.K., Charney D., Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiat. Clin. Neurosci. 9:1997;1-17.
2. Andersson J.L., Marcus M., Nomikos G.G., Svensson T.H. Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not the nigrostriatal dopaminergic system. Naunyn Schmiedeberg's Arch. Pharmacol. 349:1994;236-243.
3. Andersson J.L., Nomikos G.G., Marcus M., Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn Schmiedeberg's Arch. Pharmacol. 352:1995;374-385.
4. Angrist B., Peselow E., Rubinstein M., Rotrosen J. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology. 78:1983;128-130.
5. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol. Toxicol. 51:1982;321-329.
6. Bean A.J., Roth R.H. Extracellular dopamine and neurotensin in rat prefrontal cortex in vivo: effects of median forebrain bundle stimulation frequency, stimulation pattern, and dopamine autoreceptors. J. Neurosci. 11:1991;2694-2702.
7. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeldt N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA. 94:1997;2569-2574.
8. Brozoski T., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 205:1979;929-932.
9. Bunney B.S., Walters R.J., Roth R.H., Aghajanian G.K. Dopaminergic neurons: effects of antipsychotic drugs and amphetamine on single cell activity. J. Pharmacol. Exp. Ther. 185:1973;560-571.
10. Carlsson A. Antipsychotic drugs, neurotransmission and schizophrenia. Am. J. Psychiatry. 135:1978;164-173.
11. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-203.
12. Carlsson M., Carlsson A A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine depleted mice. J. Neural Transm. 75:1989;221-226.
13. Charléty P.J., Grenhoff J., Chergui K., De La Chapelle B., Buda M., Svensson T.H., Chouvet G. Burst firing of mesencephalic dopamine neurons is inhibited by somatodendritic application of kynurenate. Acta Physiol. Scand. 142:1991;105-112.
14. Chergui K., Charléty P.J., Akaoka C.F., Saunier J.-L., Brunet M., Buda M., Svensson T.H., Chouvet G. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vitro. Eur. J. Neurosci. 5:1993;137-144.
15. Chergui K., Nomikos G.G., Mathé J.M., Gonon F., Svensson T.H. Burst stimulation of the medial forebrain bundle selectively increases Fos-like immunoreactivity in the limbic forebrain of the rat. Neuroscience. 72:1996;141-156.
16. Chergui K., Svenningsson P., Nomikos G.G., Gonon F., Fredholm B., Svensson T.H. Increased expression of NGFI-A in the rat striatum following burst stimulation of the medial forebrain bundle. Eur. J. Neurosci. 9:1997;2370-2382.
17. Clineschmidt B.V., Martin G.E., Bunting P.R., Papp N.L. Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Develop. Res. 2:1982;135-145.
18. Cohen B.M., Lipinski J.F. In vivo potencies of antipsychotic drugs in blocking alpha 1 and dopamine D2 receptors: implications for drug mechanism of action. Life Sci. 39:1986;2571-2580.
19. Criswell H.E., Johnson K.B., Mueller R.A., Breese G.R. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J. Pharmacol. Exp. Ther. 265:1993;1001-1010.
20. Deutch A.Y. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinsons's disease. J. Neural Transm. 91:1993;197-221.
21. Deutch A.Y., Cameron D.S. Pharmacological characterization of dopamine system in the nucleus accumbens core and shell. Neuroscience. 46:1992;49-56.
22. 2 antagonist, ritanserin, on biogenic amines in the rat nucleus accumbens. Eur. J. Pharmacol. 192:1991;427-429.
23. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiat. 45:1988;71-76.
24. Fessler F.G., Sturgeon R.D., Meltzer H.Y. Effects of phencyclidine and methyl-phenidate on d-amphetamine-induced behaviors in reserpine pretreated rats. Pharmacol. Biochem. Behav. 13:1980;835-842.
25. Freeman A.S., Bunney B.S. The effects of phencyclidine and n-allylnormetazocine on midbrain dopamine neuronal activity. Eur. J. Pharmacol. 104:1984;287-293.
26. Gariano R.F., Groves P.M. Burst firing induced in midbrain dopamine neurons by stimulation of medial prefrontal and anterior cingulate cortices. Brain Res. 462:1988;194-198.
27. Gelders Y.G. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br. J. Psychiat. 155:1989;33-36.
28. 2 receptor blockers in the treatment of chronic schizophrenia. Clin. Neuropharmacol. 9:1986;325-327.
29. Gellman R.L., Aghajanian G.K. Pyramidal cells in piriform cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. Brain Res. 600:1993;63-73.
30. 2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 249:1989;673-680.
31. Gonon F.G. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience. 24:1988;19-28.
32. Grace A.A., Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopamine neurons. Neuroscience. 10:1983;301-315.
33. Grenhoff J., Svensson T.H. Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur. J. Pharmacol. 165:1989;11-18.
34. Grenhoff J., Svensson T.H. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur. J. Pharmacol. 233:1993;79-84.
35. Grenhoff J., Tung C.-S., Svensson T.H. The excitatory amino acid antagonist kynurenate induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol. Scand. 134:1988;567-568.
36. Grenhoff J., Tung C.-S., Ugedo L., Svensson T.H. Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol. Toxicol. 1:1990;29-33.
37. Grenhoff J., Nisell M., Ferré S., Aston-Jones G., Svenson T.H. Noradrenergic modulation of dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J. Neural Transm. 93:1993;11-25.
38. Hoffman R.E., McGlashan T.H. Parallel distributed processing and the emergence of schizophrenic symptoms. Schizophrenia Bull. 19:1993;119-140.
39. Hommer D.W., Zahn T.P., Pickar D., van Kammen D.P. Prazosin, a specific alpha 1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients. Psychiat. Res. 11:1984;193-204.
40. D. Ingvar, Evidence for frontal/prefrontal cortical dysfunction in chronic schizophrenia: the phenomenon of 'hypofrontality' reconsidered, in: H. Helmchen, F.A. Henn (Eds.), Biological Perspectives of Schizophrenia, Wiley, Chichester, 1987, pp. 201-211.
41. Janssen P.A.J., Niemegeers C.J.E., Schellekens K.H.L. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? Part 1: 'Neuroleptic activity spectra' for rats. Arzneimittel-Forschung Drug Res. 15:1965;104-117.
42. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiat. 148:1991;1301-1308.
43. Jentsch J.D., Redmond D.E. Jr., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955.
44. Karoum F., Karson C.N., Bigelow L.B., Lawson W.B., Wyatt R.J. Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch. Gen. Psychiat. 44:1987;604-607.
45. Karreman M., Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J. Neurochem. 66:1996;589-598.
46. Kelly P.H., Seviour P.W., Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94:1975;507-522.
47. Kolachana B.S., Saunders R.C., Weinberger D.R. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Neuroscience. 69:1995;859-868.
48. Kornhuber H. Chemistry, physiology, and neuropsychology of schizophrenia: towards an earlier diagnosis of schizophrenia I. Archiv Psychiat. Nervkrankheiten. 233:1983;15-22.
49. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiat. 51:1994;199-214.
50. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
51. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA. 93:1996;9235-9240.
52. 2 antagonist, augments fluphenazine in schizophrenic patients: A pilot study. J. Clin. Psychopharmacol. 13:1993;264-267.
53. Marcus M.M., Nomikos G.G., Svensson T.H. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur. Neuropsychopharmacol. 6:1996;29-38.
54. 1-adrenoceptor antagonism, Eur. J. Pharmacol. (1999) submitted for publication.
55. Maas J.W., Contreras S.A., Miller A.L., Berman N., Bowden C.L., Javors M.A., Seleshi E., Weintraub S. Studies of catecholamine metabolism in schizophrenia/psychosis-I. Neuropsychopharmacology. 8:1993;97-109.
56. Mathé J.M., Nomikos G.G., Hildebrand B.E., Hertel P., Svensson T.H. Prazosin inhibits MK-801 induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309:1996;1-11.
57. Mathé J.M., Nomikos G.G., Schilström B., Svensson T.H. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J. Neurosci. Res. 51:1998;583-592.
58. Mathé J.M., Nomikos G.G., Hygge Blakeman K., Svensson T.H. Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine system: Role of neuronal activity. Neuropharmacology. 38:1999;121-128.
59. J.M. Mathé, M.V. Fagerquist, T.H. Svensson, Antipsychotic-like effects of the AMPA receptor antagonist LY326325 as indicated by suppression of conditioned avoidance response in the rat, J. Neural. Transm. (1999) in press.
60. Y Meltzer H. Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 3:1995;64-75.
61. Miller D.W., Abercrombie E.D. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res. Bull. 40:1996;57-62.
62. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54:1990;1755-1760.
63. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:1997;2921-2927.
64. Murase S., Grenhoff J., Chouvet G., Gonon F.G., Svensson T.H. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci. Lett. 157:1993;53-56.
65. Murase S., Mathé J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J. Neural Transm. 91:1993;13-25.
66. Murphy B.L., Arnsten A.F., Jentsch J.D., Roth R.H. Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment. J. Neurosci. 16:1996;7768-7775.
67. Narayanan S., Willins D., Dalia A., Wallace L., Urtesky N.J. Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol. Biochem. Behav. 54:1996;565-573.
68. W.J.H Nauta, Behavioral alterations in patients with basal ganglia lesions, in: M.D. Yahr (Ed.), The Basal Ganglia, Raven Press, New York, 1976, pp. 177-80.
69. Nomikos G.G., Iurlo M., Andersson J.L., Kimura K., Svensson T.H. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology. 115:1994;147-156.
70. Nordström A.-L., Farde L., Nyberg S., Karlsson P., Halldin C., Sedvall G. D1-D2- and 5-HT2 receptor occupancy in relation to clozapine serum concentration - a PET study of schizophrenic patients. Am. J. Psychiat. 152:1995;1444-1449.
71. Ouagazzal A., Nieoullon A., Amalric M. Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum. Eur. J. Pharmacol. 252:1994;229-236.
72. Pawlowski L., Mathé J.M., Svensson T.H. Phencyclidine activates rat A10 dopamine neurons but reduces burst activity and causes regularization of firing. Acta Physiol. Scand. 139:1990;529-530.
73. Peroutka S.J., Snyder S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, a-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiat. 137:1980;1518-1522.
74. Pickar D., Su T.P., Weinberger D.R., Coppola R., Malhotra A.K., Knable M.B., Lee K.S., Gorey J., Bartko J.J., Breier A., Hsiao J. Individual variation D2 dopamine receptor occupancy in clozapine-treated patients. Am. J. Psychiat. 153:1996;1571-1578.
75. Randrup A., Munkvad I. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacology. 11:1967;300-310.
76. 2 blocker. Drug Develop. Res. 8:1986;205-211.
77. Sawaguchi T., Matsumura M., Kubota K. Dopamine enhances the neuronal activity of spatial short-term memory task in the primate prefrontal cortex. Neurosci. Res. 5:1988;465-473.
78. Sawaguchi T., Matsumura M., Kubota K. Effects of dopamine antagonists on neuronal activity to delayed response task in monkey prefrontal cortex. J. Neurophysiol. 63:1990;1401-1412.
79. Schmidt C.J., Fadayel G.M. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5HT2A receptor blockade. J. Pharmacol. Exp. Ther. 277:1996;1541-1549.
80. Schultz W., Apicella P., Ljungberg T. Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task. J. Neurosci. 13:1993;900-913.
81. Schultz W., Dayan P., Montague P.R. A neural substrate of prediction of reward. Science. 275:1997;1593-1599.
82. Servan-Schreiber D., Printz H.W., Cohen J.D. A network model of catecholamine effects: gain, signal-to-noise ratio, and behavior. Science. 249:1990;892-895.
83. 2 receptors in interneurons. Synapse. 9:1991;208-218.
84. Svensson A., Carlsson M.L., Carlsson A. Crucial role of the nucleus accumbens in the neurotransmitter interactions regulating motor control in mice. J. Neural Transm. 101:1995;127-148.
85. Svensson T.H., Tung C.-S. Local cooling of prefrontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol. Scand. 136:1989;135-136.
86. 2 antagonist ritanserin blocks the effects of prefrontal cortex inactivation on rat A10 dopamine neurons in vivo. Acta Physiol. Scand. 136:1989;497-498.
87. 2 antagonism, in: P.M. Vanhoutte, P.R. Saxena, R. Paoletti, N. Brunello, A.S. Jackson (Eds.), Serotonin From Cell Biology to Pharmacology and Therapeutics, Kluwer, London, 1993, pp 263-270.
88. 1-adrenoceptor antagonism. J. Clin. Psychopharmacol. 15:1995;11-18.
89. T.H. Svensson, J.M. Mathé, G.G. Nomikos, B. Schilström, M. Marcus, M. Fagerquist, Interactions between catecholamines and serotonin: relevance to the pharmacology of schizophrenia, in: D.S.Goldstein, G. Eisenhofer, R. McCarty (Eds.), Advances in Pharmacology, Catecholamines bridging basic science with clinical medicine, Academic Press, San Diego, 1998, pp. 814-818.
90. Taber M.T., Das S., Fibiger H.C. Cortical regulation of subcortical dopamine release: mediation via ventral tegmental area. J. Neurochem. 65:1995;1407-1410.
91. Tong Z.Y., Overton P.G., Clark D. Stimulation of the prefrontal cortex in the rat induces patterns of activity in midbrain dopaminergic neurons which resemble natural burst events. Synapse. 22:1996;195-208.
92. Tong Z.Y., Overton P.G., Clark D. Antagonism of NMDA receptors but not AMPA/kainate receptors blocks bursting in dopaminergic neurons induced by electrical stimulation of the prefrontal cortex. J. Neural Transm. 103:1996;889-904.
93. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology. 98:1989;45-50.
94. van Kammen D.P., Boronow J.J. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int. Clin. Psychopharmacol. 3:1988;111-121.
95. van Kammen D.P., Kelley M. Dopamine and norepinephrine activity in schizophrenia. Schizophrenia Res. 4:1991;173-191.
96. van Kammen D.P., Ågren H., K Yao J., O'Connor D.T., Gurklis J., Peters J.L. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am. J. Psychiat. 151:1994;379-384.
97. Verma A., Moghaddam B. The role of excitatory amino acids in prefrontal cortex function assessed by spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16:1996;373-379.
98. Volkow N.D., Hitzemann R., Wang G.-J., Fowler J.S., Wolf A.P., Dewey S.L., Handlesman L. Long-term frontal brain metabolic changes in chronic cocaine abusers. Synapse. 11:1992;184-190.
99. 2 receptor blocking agent, ritanserin, in the rat. Eur. Neuropsychopharmacol. 6:1996;305-310.
100. 1 receptors. Brain Res. 622:1993;325-329.
101. Weinberger D.R. Schizophrenia and the frontal lobe. Trends Neurosci. 11:1988;367-370.
102. Weinberger D.R., Berman K.F. Prefrontal function in schizophrenia: confounds and controversies. Philosophical Transactions of the Royal Society of London - Series B: Biol. Sci. 351:1996;1495-1503.
103. Willins D.L., Nayaranan S., Wallace L.J., Uretsky N.J. The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK-801. Pharmacol. Biochem. Behav. 46:1993;881-887.
104. Wolf M.E., White F.J., Hu X.T. Behavioral sensitization to MK-801 (dizocilpine): neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system. Behav. Pharmacol. 4:1993;429-442.
105. Wu J.C., Buchsbaum M.S., Bunney W.E. Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Jap. J. Psychopharmacol. 11:1991;47-48.